Administration Over the past 16 years, the UNC Lineberger's administrative responsibilities have grown dramatically. Physical space has doubled. Dollars directly administered have increased eight-fold from $15.1 million in 1993 to $127.3 million in 2009 -2010 (including the Center's $50M/year University Cancer Research Fund). Over the next five years the Center will continue to grow in space, funding, and personnel. Growth will follow a Research Strategic Plan that proposes continued recruitment, new research initiatives. and development/expansion of core facilities. In all these efforts, the UNC Lineberger must continue to develop and improve its administrative, technology, and communication infrastructure/operation to facilitate cancer research. Cancer Center Administration (62 FTE. $4 million/year) supports the research activities of all 295 members. Administration provides direct grant, fiscal, and other administrative services to 93 Cancer Center members and 18 core facilities. Administrative support includes: laboratory, office, and conference space;common equipment;grant and fiscal management, human resources and other administrative services, computing infrastructure / networking, communications. and imaging / printing / web services. Center support alos includes In addition, the Center provides support by organizing recruitment, developmental pilot funding, seminars, symposia, and retreats. For Year 36, the Center requests a committed level of $489,049 to support 5.80 FTEs plus costs for supplies, travel, and other operational expenses. The proposed Year 36 budget is approximately 3% higher than the current budget. The requested CCSG Administration budget represents 12.5% of the UNC Lineberger's total Administration budget and 8% of the overall CCSG budget request.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016086-37
Application #
8392156
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2012-12-01
Budget End
2013-11-30
Support Year
37
Fiscal Year
2013
Total Cost
$369,491
Indirect Cost
$72,664
Name
University of North Carolina Chapel Hill
Department
Type
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Ma, Shaohua; Paiboonrungruan, Chorlada; Yan, Tiansheng et al. (2018) Targeted therapy of esophageal squamous cell carcinoma: the NRF2 signaling pathway as target. Ann N Y Acad Sci 1434:164-172
Aung, Kyaw L; Fischer, Sandra E; Denroche, Robert E et al. (2018) Genomics-Driven Precision Medicine for Advanced Pancreatic Cancer: Early Results from the COMPASS Trial. Clin Cancer Res 24:1344-1354
Suh, Junghyun L; Watts, Brian; Stuckey, Jacob I et al. (2018) Quantitative Characterization of Bivalent Probes for a Dual Bromodomain Protein, Transcription Initiation Factor TFIID Subunit 1. Biochemistry 57:2140-2149
Brock, William J; Beaudoin, James J; Slizgi, Jason R et al. (2018) Bile Acids as Potential Biomarkers to Assess Liver Impairment in Polycystic Kidney Disease. Int J Toxicol 37:144-154
Thomas, Nancy E; Edmiston, Sharon N; Tsai, Yihsuan S et al. (2018) Utility of TERT Promoter Mutations for Cutaneous Primary Melanoma Diagnosis. Am J Dermatopathol :
Bensen, Jeannette T; Graff, Mariaelisa; Young, Kristin L et al. (2018) A survey of microRNA single nucleotide polymorphisms identifies novel breast cancer susceptibility loci in a case-control, population-based study of African-American women. Breast Cancer Res 20:45
Hall, Marissa G; Marteau, Theresa M; Sunstein, Cass R et al. (2018) Public support for pictorial warnings on cigarette packs: an experimental study of US smokers. J Behav Med 41:398-405
Thorsson, Vésteinn; Gibbs, David L; Brown, Scott D et al. (2018) The Immune Landscape of Cancer. Immunity 48:812-830.e14
Wu, Bing; Zhang, Song; Guo, Zengli et al. (2018) RAS P21 Protein Activator 3 (RASA3) Specifically Promotes Pathogenic T Helper 17 Cell Generation by Repressing T-Helper-2-Cell-Biased Programs. Immunity 49:886-898.e5
Ding, Li; Bailey, Matthew H; Porta-Pardo, Eduard et al. (2018) Perspective on Oncogenic Processes at the End of the Beginning of Cancer Genomics. Cell 173:305-320.e10

Showing the most recent 10 out of 1525 publications